Skip to content
Loading…
Iambic Therapeutics Inc. shares soared 16% in its trading debut after the clinical-stage cancer drugmaker and technology firm raised $150 million in a US initial public offering.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.